Analyst Has Confidence in Biotech's Path
Research Report

1. Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Sernova Biotherapeutics Inc., June 26, 2025

Disclaimers
This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be
privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let
us know by e-mail reply to [email protected] and delete it from your system; you may not copy this message or
disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.
H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the
potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity
is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the
potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price
objectives are subject to external factors including industry events and market volatility.
RETURN ASSESSMENT
Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the
common stock of companies within the same sector.
Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index
comprised of all the common stock of companies within the same sector.
Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of
all the common stock of companies within the same sector.
Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement
of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company
or one of its affiliates or subsidiaries within the past 12 months.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.
I, Joseph Pantginis, Ph.D., Joshua Korsen, Ph.D., Matthew Keller, Ph.D., Sara Nik, Ph.D. and Lander Egaña Gorroño, Ph.D. ,
certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities
or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific
recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an
officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Sernova Corp.
and Vertex Pharmaceuticals Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of May 31, 2025 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of
Sernova Corp. and Vertex Pharmaceuticals Inc..
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of
publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any
specific investment banking services or transaction but is compensated based on factors including total revenue and profitability
of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Sernova Corp. for non-investment banking services in the previous 12
months.
The Firm or its affiliates did not receive compensation from Sernova Corp. and Vertex Pharmaceuticals Inc. for investment
banking services within twelve months before, but will seek compensation from the companies mentioned in this report for
investment banking services within three months following publication of the research report.
The Firm does not make a market in Sernova Corp. and Vertex Pharmaceuticals Inc. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment
objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational
purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction
where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to
any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.
No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional
information available upon request.
H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is
not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial
situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness
of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.
H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market
commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.
H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time
have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants)
thereof of covered companies referred to in this research report.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being
accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of
this report and are subject to change without notice.
Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal
Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.
H.

On June 23, 2025, H.C. Wainwright analysts Dr. Joseph Pantginis, Dr. Joshua Korsen, Dr. Matthew Keller, Dr. Sara Nik, and Dr. Lander Egaña Gorroño reiterated a Buy rating on Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) with a CA$6.00 price target, representing 3,650% upside from the share price at the time of the report of CA$0.16.

The analysts cited Vertex Pharmaceuticals' advances in cell therapy as helping to de-risk Sernova's strategy while maintaining that the implantable delivery system remains a key differentiator.

Clinical Validation and Competitive Positioning

Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) presented updated data from its Phase 1/2 zimislecel (VX-880) program at the American Diabetes Association conference, evaluating stem cell-derived islet cell therapy in type 1 diabetes patients. The study included 12 patients with type 1 diabetes and impaired hypoglycemia awareness who received a full dose, single infusion, and were followed for at least one year. Results demonstrated durable, glucose-responsive C-peptide production in all participants through one year, achievement of ADA glycemic control targets across all patients, and reduction in exogenous insulin use in 10 of 12 patients.

The analysts noted that while both approaches aim to restore insulin production by replacing damaged beta cells, they differ in delivery methods, with Vertex using stem cell-derived cells infused via the hepatic portal vein and Sernova using donor-derived islets placed into a pre-vascularized Cell Pouch device. The analysts emphasized that "Vertex's results are a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D."

Recent Clinical Progress and Trial Results

Sernova announced new data from 12 patients in its ongoing Phase 1/2 clinical trial assessing the Cell Pouch device in type 1 diabetes. The study consists of Cohort A utilizing an 8-channel Cell Pouch device and Cohort B employing a 10-channel device with greater than 50% increased capacity compared to the 8-channel device, combined with an optimized immunosuppressive regimen.

Key clinical outcomes demonstrated 8 of 12 patients (66%) achieving insulin independence, 7 of 12 patients (58%) showing C-peptide levels of 0.3 ng/mL or greater indicating successful islet cell engraftment, and 9 of 12 patients (75%) achieving HbA1c levels below 7.0%. The analysts noted that C-peptide levels of 0.3 ng/mL represent "a threshold for graft function" and indicate "successful islet cell engraftment and insulin production by islets transplanted into the Cell Pouch."

Strategic Development and Market Opportunity

The Cell Pouch system creates a pre-vascularized, tissue-integrated environment for transplanted islets, which the analysts believe potentially improves long-term islet survival and function compared to alternative delivery methods. A confirmatory Cohort C is expected to commence in the second half of 2025, with full Phase 1/2 trial data anticipated.

The analysts project the Cell Pouch system could reach the U.S. market in 2027, assigning a 25% probability of success on peak sales of $2.3 billion based on approximately 2.1% market penetration in the hypoglycemic unaware population. They emphasized that "the market could be significantly larger with the broader T1D population and the continuing dramas surrounding insulin supply and its costs."

Financial Position and Valuation Framework

Sernova maintains CA$6.01 million in cash with no debt and 328.5 million shares outstanding, resulting in a market capitalization of CA$53 million and enterprise value of CA$47 million. The company currently generates no revenue and reports minimal earnings per share.

The analysts' valuation methodology utilizes a clinical net present value model focused on addressing hypoglycemic unawareness patients. They highlighted that current data support "at the minimum, a two-year, cell implant impact on insulin independence, which... has a significant impact on the broader healthcare costs of T1D patients."

Risk Assessment and Investment Outlook

Primary risks include potential failed or inconclusive clinical trials, inability to secure adequate funding for continued development, and occurrence of dilutive capital raises.

However, the analysts maintain confidence in the platform's differentiated approach and the validation provided by Vertex's parallel success in cell-based diabetes therapy.